Trial Profile

A Phase II study of targeting trastuzumab resistant HER2+ breast cancer using INB03 as part of combination therapy with Lapatinib

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 14 May 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 May 2020 According to an INmune Bio media release, the company announced presentation of a pre-clinical study at the New York Academy of Science Frontiers in Cancer Immunotherapy 2020 demonstrating the combination of INB03 with lapatinib reverses resistance to therapy in trastuzumab resistant HER2+ breast cancer. The study work lays the groundwork for and provides rational for use of INB03 and Lapatinib in this upcoming Phase II trial.
11 Mar 2020 According to an INmune Bio media release, the company expects to enroll first patient in this study in mid-2020.
20 Dec 2019 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com